Ardelyx Receives New Patent for Tenapanor

Rhea-AI Summary

Ardelyx (Nasdaq: ARDX) announced that the USPTO issued U.S. Patent No. 12,539,299 titled “Oral Formulations of Tenapanor”, covering the commercial formulations of IBSRELA and XPHOZAH, with an expiration date of November 26, 2042.

The company said it will submit the patent for listing in the FDA Orange Book. The November 26, 2042 expiry reflects a Patent Term Adjustment due to USPTO delays and updates prior communications.

Positive

• U.S. Patent No. 12,539,299 issued covering tenapanor formulations
• Patent protects IBSRELA and XPHOZAH commercial formulations until 11/26/2042
• Company will seek Orange Book listing, strengthening regulatory protection

Negative

• Patent expiry remains finite at November 26, 2042, limiting exclusivity duration
• Patent term adjustment credited to USPTO delays, not new company innovation

News Market Reaction – ARDX

-0.64%

1 alert

-0.64% News Effect

On the day this news was published, ARDX declined 0.64%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Patent number: U.S. Patent No. 12,539,299 Patent expiration: November 26, 2042 Stated expiry: Fall 2042

3 metrics

Patent number U.S. Patent No. 12,539,299 Oral Formulations of Tenapanor

Patent expiration November 26, 2042 Tenapanor oral formulations covering IBSRELA and XPHOZAH

Stated expiry Fall 2042 Management description of new patent term

Market Reality Check

Price: $5.30 Vol: Volume 2622968 is at 0.41...

low vol

$5.30 Last Close

Volume Volume 2622968 is at 0.41x the 20-day average of 6339504, indicating subdued trading activity. low

Technical Shares at 7.79 are trading above the 200-day MA at 5.31 and sit 7.26% below the 52-week high of 8.4.

Peers on Argus

Momentum scanner shows no sector-wide move; no peers are in the real-time moment...

Momentum scanner shows no sector-wide move; no peers are in the real-time momentum list. Notable peers like AUPH (+4.75%), MNKD (+4.52%), VCEL (+2.58%) and VERA (+5.4%) had gains, but these were not flagged as a coordinated momentum event.

Historical Context

5 past events · Latest: Jan 28 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 28	Phase 3 trial start	Positive	-0.4%	First patient dosed in ACCEL Phase 3 CIC study for IBSRELA.
Jan 08	Revenue outlook	Positive	+20.1%	Strong 2025 product revenue and raised 2026 guidance for IBSRELA and XPHOZAH.
Nov 07	Clinical data update	Positive	+1.1%	Real-world XPHOZAH data showing phosphate reduction and patient satisfaction.
Nov 05	Investor conference	Neutral	+6.3%	Participation in Jefferies Global Healthcare Conference fireside chat.
Nov 04	Investor conference	Neutral	-5.4%	CEO participation in Wedbush Rewind ASN investor conference webcast.

Pattern Detected

Recent news has generally been positive, but price reactions have been mixed, with more divergence than alignment, including sizable moves on neutral conference headlines.

Recent Company History

Over the past few months, Ardelyx has reported several milestones, including a Phase 3 ACCEL trial launch for IBSRELA, strong preliminary 2025 revenue growth for IBSRELA and XPHOZAH, and real-world XPHOZAH data showing phosphate reductions and patient satisfaction. Investor events at healthcare conferences generated notable but inconsistent price moves. Against this backdrop, the new patent extending tenapanor formulation protection to 2042-11-26 further reinforces the company’s intellectual property around IBSRELA and XPHOZAH.

Market Pulse Summary

This announcement strengthens Ardelyx’s intellectual property by securing U.S. Patent No. 12,539,299...

Analysis

This announcement strengthens Ardelyx’s intellectual property by securing U.S. Patent No. 12,539,299 for tenapanor oral formulations, extending coverage of IBSRELA and XPHOZAH to November 26, 2042. In the context of recent clinical progress and revenue growth for these brands, the longer patent term reinforces the franchise’s duration. Investors may monitor future updates on the ACCEL Phase 3 trial, commercialization trends, and additional regulatory developments to assess how this protection supports the broader strategy.

Key Terms

tenapanor, ibsprela, united states patent and trademark office, uspto, +3 more

7 terms

tenapanor medical

"The patent relates to the formulation of tenapanor and covers the commercial..."

Tenapanor is an oral drug that works in the gut by blocking a specific transport protein (NHE3), which reduces the absorption of certain salts and can change bowel habits; it is being developed to treat conditions such as high phosphate levels in kidney disease and constipation‑predominant irritable bowel syndrome. For investors, tenapanor matters because clinical trial outcomes, regulatory decisions and how it compares with existing therapies determine whether it can become a widely used, revenue‑generating medicine — think of it as a new tool that could replace or complement current treatment options.

ibsprela medical

"covers the commercial formulations of IBSRELAae (tenapanor) and XPHOZAHae..."

A prescription medicine approved to treat irritable bowel syndrome with constipation (IBS‑C), offered as an oral tablet to relieve abdominal pain and constipation symptoms. Investors watch such drugs because successful approvals, clear clinical benefit, and strong patient uptake can drive steady prescription revenue and influence a company’s growth prospects much like a new product line can reshape sales for a consumer brand.

united states patent and trademark office regulatory

"announced that the United States Patent and Trademark Office (USPTO) has issued..."

A U.S. government agency that reviews and issues patents for inventions and registers trademarks for brand names and logos, acting like an official office that grants property deeds for ideas and branding. Investors care because patents and trademarks can create legal barriers to competition, support higher pricing, enable licensing revenue, and affect a company’s long‑term value and legal risk—so decisions by this office can materially influence a firm’s prospects.

uspto regulatory

"United States Patent and Trademark Office (USPTO) has issued U.S. Patent No..."

United States Patent and Trademark Office (USPTO) is the federal agency that reviews and issues patents for inventions and registers trademarks for brand names and logos. For investors, USPTO decisions act like a gatekeeper for a company’s legal right to exclude competitors — similar to a property deed for ideas and brands — which can protect revenue, support pricing power, and affect a company’s long‑term value and risk profile.

food and drug administration regulatory

"The patent will be submitted to the Food and Drug Administration for listing..."

A government agency that reviews and regulates medicines, medical devices, food safety, and related products to ensure they are safe and effective for public use. Investors watch its actions like a referee’s calls: approvals, warnings, inspections or recalls can directly affect a product’s ability to reach the market, a company’s sales and costs, and overall business risk and valuation.

orange book regulatory

"listing in the Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book)..."

A publicly maintained FDA database that lists approved prescription drugs and notes which versions are considered interchangeable with brand-name products, along with key patent and exclusivity dates. Think of it as a product roster plus an expiration calendar: investors use it to see when a drug’s protection ends and generic competition can enter, which can directly affect a company’s sales, future revenue and stock value.

patent term adjustment regulatory

"reflects a Patent Term Adjustment resulting from USPTO delays."

Patent term adjustment is extra time added to a patent’s normally fixed expiration to compensate for delays caused by the patent office during examination. For investors, it changes how long a company can legally exclude competitors and earn monopoly-style profits from a product, much like extending a store’s exclusive sales license when regulators hold up approval. Longer adjustments can increase projected cash flow and valuation for patent-dependent businesses.

AI-generated analysis. Not financial advice.

New patent covers IBSRELA® and XPHOZAH® and expires in 2042

WALTHAM, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,539,299 titled “Oral Formulations of Tenapanor” with an expiration date of November 26, 2042. The patent relates to the formulation of tenapanor and covers the commercial formulations of IBSRELA^® (tenapanor) and XPHOZAH^® (tenapanor). The patent will be submitted to the Food and Drug Administration for listing in the Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book) for both products.

“We are pleased to have been granted this patent for IBSRELA and XPHOZAH, which expires in fall of 2042,” said Mike Raab, president and chief executive officer of Ardelyx. “This is an important step in extending protections for our portfolio of first-in-class medicines in therapeutic areas where there continues to be significant unmet patient need. We are committed to executing a comprehensive intellectual property strategy that enables us to continue driving meaningful impacts for patients and creating lasting value for our shareholders.”

The expiration date of November 26, 2042 for this patent is an update from information previously communicated by the Company, and reflects a Patent Term Adjustment resulting from USPTO delays.

About IBSRELA^® (tenapanor)
IBSRELA (tenapanor) is a locally acting inhibitor of the sodium/hydrogen exchanger 3 (NHE3), an antiporter expressed on the apical surface of the small intestine and colon primarily responsible for the absorption of dietary sodium. By inhibiting NHE3 on the apical surface of the enterocytes, tenapanor reduces absorption of sodium from the small intestine and colon, thus retaining luminal water content, which accelerates intestinal transit time and results in a softer stool consistency. IBSRELA has also been shown to reduce abdominal pain by decreasing visceral hypersensitivity and by decreasing intestinal permeability in animal models. In a rat model of colonic hypersensitivity, tenapanor reduced visceral hyperalgesia and normalized colonic sensory neuronal excitability.

About XPHOZAH^® (tenapanor)
XPHOZAH, discovered and developed by Ardelyx, is a first-in-class, phosphate absorption inhibitor with a differentiated mechanism of action that acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3), thereby reducing phosphate absorption through the paracellular pathway, the primary pathway of phosphate absorption. XPHOZAH is a single tablet, taken twice daily. Diarrhea was the most common side effect experienced by patients taking XPHOZAH in clinical trials. Please see additional full Prescribing Information.

IMPORTANT SAFETY INFORMATION (IBSRELA)

WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS IBSRELA is contraindicated in patients less than 6 years of age; in nonclinical studies in young juvenile rats administration of tenapanor caused deaths presumed to be due to dehydration. Avoid use of IBSRELA in patients 6 years to less than 12 years of age. The safety and effectiveness of IBSRELA have not been established in patients less than 18 years of age.

CONTRAINDICATIONS

• IBSRELA is contraindicated in patients less than 6 years of age due to the risk of serious dehydration.
• IBSRELA is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction.

WARNINGS AND PRECAUTIONS
Risk of Serious Dehydration in Pediatric Patients

• IBSRELA is contraindicated in patients below 6 years of age. The safety and effectiveness of IBSRELA in patients less than 18 years of age have not been established. In young juvenile rats (less than 1 week old; approximate human age equivalent of less than 2 years of age), decreased body weight and deaths occurred, presumed to be due to dehydration, following oral administration of tenapanor. There are no data available in older juvenile rats (human age equivalent 2 years to less than 12 years).
• Avoid the use of IBSRELA in patients 6 years to less than 12 years of age. Although there are no data in older juvenile rats, given the deaths in younger rats and the lack of clinical safety and efficacy data in pediatric patients, avoid the use of IBSRELA in patients 6 years to less than 12 years of age.

Diarrhea
Diarrhea was the most common adverse reaction in two randomized, double-blind, placebo-controlled trials of IBS-C. Severe diarrhea was reported in 2.5% of IBSRELA-treated patients. If severe diarrhea occurs, suspend dosing and rehydrate patient.

MOST COMMON ADVERSE REACTIONS
The most common adverse reactions in IBSRELA-treated patients (incidence ≥2% and greater than placebo) were: diarrhea (16% vs 4% placebo), abdominal distension (3% vs <1%), flatulence (3% vs 1%) and dizziness (2% vs <1%).

INDICATION
IBSRELA (tenapanor) is indicated for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in adults.

Please see full Prescribing Information, including Boxed Warning, for additional risk information.

IMPORTANT SAFETY INFORMATION (XPHOZAH)

CONTRAINDICATIONS

XPHOZAH is contraindicated in:

• Pediatric patients under 6 years of age
• Patients with known or suspected mechanical gastrointestinal obstruction

WARNINGS AND PRECAUTIONS
Diarrhea
Patients may experience severe diarrhea. Treatment with XPHOZAH should be discontinued in patients who develop severe diarrhea.

MOST COMMON ADVERSE REACTIONS
Diarrhea, which occurred in 43-53% of patients, was the only adverse reaction reported in at least 5% of XPHOZAH-treated patients with CKD on dialysis across trials. The majority of diarrhea events in the XPHOZAH-treated patients were reported to be mild-to-moderate in severity and resolved over time, or with dose reduction. Diarrhea was typically reported soon after initiation but could occur at any time during treatment with XPHOZAH. Severe diarrhea was reported in 5% of XPHOZAH-treated patients in these trials.

INDICATION
XPHOZAH (tenapanor), 30 mg BID, is indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

For additional safety information, please see full Prescribing Information.

About Ardelyx
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA^® (tenapanor) and XPHOZAH^® (tenapanor). The company’s pipeline includes the Phase 3 development of IBSRELA for chronic idiopathic constipation (CIC) and RDX10531, a next-generation NHE3 inhibitor with potential application across multiple therapeutic areas. Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL^® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.

Investor and Media Contacts:
Caitlin Lowie
clowie@ardelyx.com

FAQ

What does the new Ardelyx (ARDX) patent cover and when does it expire?

The patent covers oral formulations of tenapanor, including IBSRELA and XPHOZAH, expiring November 26, 2042. According to the company, U.S. Patent No. 12,539,299 names the formulation claims and sets the expiry date after a Patent Term Adjustment.

Will Ardelyx (ARDX) list the tenapanor patent in the FDA Orange Book?

Yes, the company plans to submit the patent for Orange Book listing for both products. According to the company, listing will record the patent against approved drug products to support regulatory exclusivity and patent notification processes.

How does the November 26, 2042 expiration affect IBSRELA and XPHOZAH exclusivity?

The expiration gives Ardelyx exclusive formulation protection through November 26, 2042, limiting generic competition until then. According to the company, this term results from a Patent Term Adjustment tied to USPTO processing delays.

What is a Patent Term Adjustment and why did Ardelyx receive one for ARDX?

A Patent Term Adjustment extends patent life for USPTO administrative delays, which changed the expiry to November 26, 2042. According to the company, the updated date reflects USPTO delays rather than changes to the underlying claims.

Does the new patent create new market or revenue commitments for Ardelyx (ARDX)?

The patent secures formulation protection but does not itself promise revenue or sales figures. According to the company, the issuance supports its intellectual property strategy aimed at protecting marketed products and shareholder value.